The prostate cancer minimally invasive surgical device market in North America and Europe is estimated to be $14.2 billion in 2011 and expected to reach $24.9 billion in 2016 at a CAGR of 11.9% over the period 2011 to 2016. The monitoring and visualization segment is the leading market contributor with a share of around 38% in 2011.
Browse full report at: Minimally Invasive Surgery Market
Prostate cancer is the second most leading cause of cancer associated mortality among men after lung cancer. In 2010, more than 1.9 million people have been diagnosed with the prostate cancer across the world. African Americans and whites are most affected with this disease. Old age, heredity, lifestyle aspects such as smoking and diet rich in red meat are the major factors increasing the risk of getting affected with the disease.
The estimated market of North America & Europe minimally invasive prostate cancer surgical device is USD 14.2 billion in 2011 and expected to realize a growth of 11.9% over the period of 2011 to 2016. U.S. is the leading market of minimally invasive prostate cancer surgical devices with an estimated share of around 56% (USD 8 Billion) in 2011and expected to become USD 13 billion (52%) in 2016. Germany is the second high growth market and is the leading market in Europe. It has the estimated market share of about 11% in 2011and is expected to reach USD 3 billion in 2016.
Digital Rectal Exam (DRE), Prostate Biopsy, Prostate Specific Antigen (PSA) blood test, bone scan, ultrasound, CT scan, MRI, lymph node biopsy and ProstaScint monoclonal antibody scanare some of the methods used to diagnose the prostate cancer. Among the surgical techniques, minimally invasive have become quite popular in the last decade.Laparoscopy, cryosurgery, brachytherapy and robotic surgery are the commonly practices surgical techniques while performing minimally invasive surgeries for the treatment of prostate cancer. Laparoscopy has the comparative high adoption rate among the surgeons, while surgical robot has significantly emerged as the top preference in past decade. In spite of high cost of robots (close to USD 1.5 million), their adoption has considerably increased due to better precision, dexterity, improved surgery control, reduced risk of surgical side effects such as impotency, shorter hospital stay, lesser pain, quicker recovery.
Browse: Prostate Cancer Market
Prostate cancer minimally invasive surgery market in North America & Europe is quiteconsolidated. Global players like Ethicon Endo Surgery, Covidien, Intuitive Surgical, Boston Scientific Corporation and Carefusion Corporation holds over 4/5th of the market in 2010. Ethicon Endo Surgery is the market leader with control over 1/3rdof market, followed by Covidien. Further, Intuitive Surgical, Boston Scientific Corporation, Carefusion Corporation and Olympus are closely positioned with shares between 13% and 5%.
Scope and Overview
The objective of the study on “Minimally Invasive Prostate cancer Surgery Market in North America and Europe” is to gain detailed market insights for minimally invasive surgical techniques and devices used to treat prostate cancer in developed economies where the reported cancer incidence is very high. The market is analyzed on the basis of growth trends, ongoing developments, market penetration and revenue share.The report also covers the strategies followed by “Minimally Invasive Prostate cancer Surgery Market in North America and Europe” players.